Lipoprotein (a) levels in those with high molecular weight apo (a) isoforms may remain low in a significant proportion of patients with end-stage renal disease.

BACKGROUND: Studies have reported an increase in median Lipoprotein (Lp) (a) in patients with high molecular weight (HMW) apolipoprotein (apo) (a) isoforms and renal impairment. Some studies identify Lp (a) levels as a risk factor for vascular disease in renal failure whilst others have demonstrated an association with apo (a) isoform type and vascular disease. METHODS: A total of 239 patients at end-stage renal failure (ESRF) were studied prior to the initiation of dialysis. Blood was taken for Lp (a) levels and apo (a) isoforms. Clinical vascular disease (CVD) was assessed on the basis of clinical history and Rose questionnaire. The control group for Lp (a) levels consisted of 228 healthy volunteers. RESULTS: Despite a higher median Lp (a) level in those with HMW isoforms, 30% of patients had Lp (a) levels <10 mg/dl. Overall, 49% patients were identified as having CVD. Diabetes, smoking history and Lp (a) levels were significantly associated with CVD in logistic regression analysis, although when patients with low molecular weight (LMW) and HMW isoforms were analysed separately, Lp (a) levels were not significantly associated with CVD in those with LMW isoforms. The rates of CVD in those with HMW isoform and low Lp (a) levels were significantly lower than those with HMW isoforms and elevated Lp (a) levels, 34 vs 57% (P < 0.01). CONCLUSIONS: Although median Lp (a) levels in those patients at ESRF with HMW isoforms are higher than controls, in a third of such patients Lp (a) levels remain relatively low. These patients have lower rates of CVD than those with high levels of Lp (a).     

ENDOSCOPIC PANCREATIC STENTING IN CHRONIC PANCREATITIS WITH DUCTAL DILATION PROXIMAL TO A STRICTURE: A SAFE and EFFECTIVE PROTOCOL

After removal of intraductal stones, a 10‐Fr or 7‐Fr pancreatic stent was placed in 16 patients with upstream ductal dilation proximal to a stricture of the main pancreatic duct. Stents were removed after a mean duration of 52.5 days. Nine patients underwent repeated stenting. About one year after removal of the initial stent, when the remaining upstream ductal dilation was found on follow‐up pancreatograms, the next stent was replaced. Repeated stenting improved outflow of pancreatic juice more effectively than one‐time stenting. Correlation between long‐term pain relief without recurrence of intraductal stones and reduction of duct diameter was also shown. Stent occlusion was observed in 14 of 30 stents. Stent occlusion was frequently associated with recurrence of pancreatitis and intraductal stones, and was also associated with morphologic changes in the pancreatic ductal system. Although there were no significant differences between stent patency of the initial stents and that of the next stents, stent patency of 10‐Fr stents was superior to that of 7‐Fr stents. 10‐Fr stents should be removed within 8 weeks and 7‐Fr stents should be removed within 4 weeks for the prevention of stent occlusion. Repeated stenting with short‐term stenting is therefore considered a safe and effective protocol of endoscopic pancreatic stenting.     

实验教学改革与学生综合素质培养的实践

在培养医学检验专业学生中 ,通过设置综合性、设计开放性实验 ,改革实验考核方法和内容 ,强化毕业实习 ,以深化实验室体制改革。以学生为中心 ,培养学生综合素质、创新精神和实践能力 ,全面推进教学质量提高     

SARS流行期间肺炎患者的临床表现和胸部影像变化的探讨

目的 探讨SARS流行期间肺炎患者的临床表现和胸部影像变化特点。方法 对76例SARS流行期间发热留观室收治的肺炎患者的临床表现及胸部影像进行分析。结果 (1)此组肺炎患者多为青壮年(占60．53％)，无固定职业或职业性质流动性较大者居多(69．74％)；(2)临床特征主要是发热，以中高热为多见(80．26％)，发病早期部分患者呼吸道症状并不明显(67．10％)，外周血WBC在正常或低于正常范围(85．53％)，淋巴细胞比例减少(75．00％)；(3)肺部CT表现为不同程度的炎性浸润；病灶形态以斑片状和球形多见(77．63％)；病灶常位于肺周边，常出现支气管气像；动态观察病变影像大多无明显进展(88．16％％)，经治疗均完全吸收。结论 SARS流行期间普通肺炎与非典型肺炎有相似的临床及胸部影像表现；肺部CT扫描能早期发现肺炎患者的异常阴影，明显优于胸片，但无特异性。因此，在SARS流行期间发热诊室医务人员应加强肺部炎性改变的早期诊断和鉴别诊断水平。     

血浆置换床边治疗重型肝炎临床观察

目的探讨血浆置换(简称PE)床边治疗重型肝炎的临床疗效。方法60例病例采用常规内科治疗加PE治疗,比较PE治疗前后临床症状缓解时间及血生化变化。结果临床症状缓解迅速,黄疸减退,白蛋白、胆碱脂酶升高,PT恢复,补体上升,不影响肾功及电解质。结论PE为重型肝炎一种行之有效的治疗方法。     

生精丸治疗男性不育60例临床研究

目的观察生精丸对男性不育的治疗作用.方法选择120例男性不育患者,随机分为治疗组和对照组.每组60例,分别给予生精丸和五子衍宗丸治疗.治疗前后以WLJY-9000伟力彩色精子质检系统进行精液参数分析,并检测血液睾酮(T)水平,同时观察病人服用生精丸期间有无明显不良反应.结果治疗组精子密度、活率、活力以及运动参数和睾酮水平等指标均明显高于对照组(P＜0.05),痊愈率、显效率及总有效率亦高于对照组(P＜0.05),且服药期间无明显的不良反应.结论生精丸有从整体上纠正精液异常的功效,能使病人精子数量、质量、睾酮水平得到提高.     

欧丹西酮预防曲马多硬膜外术后镇痛期间恶心、呕吐的定量研究

目的　寻找欧丹西酮 (Ondansetron)预防妇产科手术后曲马多连续硬膜外镇痛期间恶心和呕吐的最佳剂量。方法　ASAⅠ～Ⅱ级妇产科手术病人 12 0例 ,随机分为 4组 (n =30 ) ,于关腹后接镇痛泵前 (配方为曲马多 80 0mg+布比卡因 112 .5mg ,总量 10 0ml,泵速 2ml/h)分别接受欧丹西酮 2mg、4mg、6mg和生理盐水 2ml静注。观察镇痛期不同时点的VAS值和 0～ 2 4h的恶心、呕吐发生率。结果　 4组VAS均值无明显差异 (P >0 .0 5 )。在 0～2 4h ,恶心 :2mg组 30 .4 % (7) ,4mg组 3.3% (1) ,6mg组 3.3% (1)和生理盐水组 4 6 .7% (14 ) ;呕吐 :2mg组2 0 .0 % (6 ) ,4mg组 3.3% (1) ,6mg组 3.3% (1)生理盐水组 4 3.3% (13)。在预防恶心和呕吐两个事件方面 ,所有用药组与对照组相比均有显著差异 (P <0 .0 5 ) ;在用药组中 ,2mg组与 4mg和 6mg组间比较P <0 .0 5 ,而后 2个剂量组间无差别。结论　本文 3个剂量组的欧丹西酮均有预防妇产科手术后曲马多连续硬膜外镇痛期间恶心和呕吐的作用 ,其中以 4mg组最优。     

学龄儿童单纯性肥胖对智商影响的meta分析

目的 应用meta分析正确评价学龄儿童单纯性肥胖对智商的影响。方法 对检索到的符合标准的11篇相关文献进行meta分析，选择随机效应模型进行统计处理。结果 单纯性肥胖组与对照组儿童智商比较，平均较应尺度为-0．3385，平均效应尺度的95％可信区间为-0．8036～0．1266。结论 单纯性肥胖对智商影响的meta分析结果无统计学意义。     

慢性阻塞性肺疾病前驱性呼吸衰竭患者呼吸驱动的改变

目的探讨慢性阻塞性肺疾病(COPD)和COPD前驱性呼吸衰竭(前驱呼衰)患者中枢呼吸驱动的改变;评价界定COPD前驱性呼吸衰竭的临床意义.方法试验对象为COPD前驱性呼吸衰竭、COPD尚未达前驱性呼吸衰竭的患者和健康对照者各30名.所有受试者均进行如下参数的测定:动脉血气分析;常规肺功能,主要以第1秒用力呼气容积(FEV1)占预计值的百分比(FEV1%)来评价;中枢呼吸驱动水平,以0.1 s口腔阻断压(P0.1)、校正中枢呼吸驱动(以每分通气量来校正,即P0.1/MV)和吸气阻抗P0.1/VT/Ti)等来评价.结果P0.1和P0.1/MV在COPD前驱呼衰组明显高于正常对照组和未达前驱呼衰组,P0.1/VT/Ti在COPD前驱呼衰组和未达前驱呼衰组明显高于正常对照组(P=0.002);P0.1,P0.1/MV,P0.1/VT/Ti与PaO2,FEV1%呈显著负相关(rs=-0.769,-0.495,-0.543;-0.747,-0.480,-0.526,P均＜0.01);与PaCO2呈显著正相关(rs=0.270,0.312,0.369,P分别为＜0.05,＜0.01,＜0.01).结论COPD前驱呼衰患者呼吸储备能力减低,呼吸效率下降;P0.1,P0.1/MV,P0.1/VT/Ti等参数在推断患者神经-肌力输出水平与呼吸衰竭发生阈值方面具有较大的意义.当COPD进展至前驱呼衰阶段,从血气分析、肺功能检查到呼吸驱动水平都发生了显著的改变,从而提示界定此阶段具有一定的临床意义.     

双功能混合催化剂上含氮合成气直接制取二甲醚的宏观动力学

在温度220～260°C,压力5MPa,转筐转速2600r/min,空速1000～2000mL/(g·h)条件下,建立了工业级双功能混合催化剂上含氮合成气直接制二甲醚的宏观动力学模型,并获得了模型参数。统计检验和残差分析表明模型可靠。根据获得的宏观动力学及本征动力学的模拟计算,比较了两模型下温度及含氮量对反应的影响。由于含氮量影响反应组分的分压,进而影响CO的转化率,还通过影响反应组分在催化剂颗粒内的内扩散来影响产物的选择性,但总的结果是内扩散的存在减弱了催化剂的协同效应。